Phase IIa Sjögren Syndrome Case Study available
A single-centre study with salivary gland biopsies and complex biomarkers in 27 Sjögren's patients enrolled within 10 months in CRO's Phase I Unit in Berlin.
As of today you can access our first case study that illustrates how - with our help - you can reach Proof of Concept faster. This particular case study deals with a Phase IIa, single dose, double-blind, placebo-controlled, parallel study to assess the PD, PK and safety and tolerability of a monoclonal antibody in 27 patients with primary Sjögren syndrome.
In this study we combined extensive therapeutic area expertise, operational excellence and our unrivalled recruitment capabilities to run the study single-centre with challenging assessments - such as labial salivary gland biopsies and high-resolution ultrasounds - and complex biomarkers being integrated seamlessly into trial conduct at our Berlin unit.